The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies… While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.
– Goldman Sachs analyst (via).
No wonder, other forms of medicines aren’t popular and media ensures that they never become popular.
Right?
“Is curing patients a sustainable business model?” Analysts ask
You may also like
Want to make a living as a creator? Use these 15 lessons from @shl, @naval, and @benthompson to become a successful creator 🧵1. Many Leaderboards There will always be someone at the top of the leader board. BUT, the internet makes it possible for there to be multiple leaderboards. Someone can be...
Tech
ISACA’s new certification in emerging technologies can make you stand out from the crowd in the post-pandemic times
During the past few years, technological advances tried making inroads intobusinesses. COVID-19 pandemic turned the tables now and have laid a clear roadmaking technology backed business model a necessity and no longer a privilege. Also, with the unprecedented changes the Covid-19 pandemic have...
1. The Collisons think super long-term. Employees talk about how the company doesn’t think in years…it thinks in decades. That comes from the top.2. They are hyper-patient recruiters In an interview with @johnolilly, @patrickc talked about how he courted key recruits for *more than...
